Japan 2014: Regulatory Moves, Suspect Practices, And Acquisitions
This article was originally published in PharmAsia News
If you missed any of the major news and analysis from Japan in 2014, here's your opportunity to check out PharmAsia News' view of the most important stories of the year. If there was any one overriding trend to pick out, it was the push towards more efficient regulation and the shaping of policy to support medical research in a rapidly aging society.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.